Acetylcholinesterase inhibitors in assisted living: patterns of use and association with retention.
Acetylcholinesterase inhibitors in assisted living: patterns of use and association with retention.
复制标题
辅助生活中的乙酰胆碱酯酶抑制剂：使用模式及其与保留的关联。
DOI：
10.1002/gps.1859
复制
发表时间：
2008
影响因子：
4
通讯作者：
Lyketsos,ConstantineG
中科院分区：
文献类型：
--
作者：
Rosenblatt,Adam;Samus,QuincyM;Onyike,ChiadiU;Baker,AlvaS;McNabney,Matthew;Mayer,LawrenceS;Brandt,Jason;Lyketsos,ConstantineG
ObjectivesTo描述模式的乙酰胆碱酯酶抑制剂（ACI）的使用在辅助生活（AL）的人口，并保留在AL.MethodsAs的马里兰州辅助生活研究（MD-AL）的一部分，198名居民的22 AL进行了评估。痴呆症被诊断为134，特别是阿尔茨海默病（AD）在79，由专家共识小组。收集ACI药物和剂量的数据。每6个月记录一次生命状态和位置。其他数据包括年龄，居住时间，一般医疗健康评级（GHMR），简易精神状态检查（MMSE），神经精神量表（NPI），康奈尔抑郁量表痴呆（CSDD）和非精神药物的数量。34.5%的轻度至中度AD患者正在服用ACI。仅2/7的接受rivastigmine治疗的受试者服用了足够的剂量。与AD的ACI的参与者没有显着差异，从那些没有ACI的在任何次要措施，除了年龄和居住时间，那些代理人有点年轻，最近承认。对于AD患者，只有ACI的使用与6个月时AL的保留显著相关，死亡或出院至更高水平护理的相对风险为0.217。基线MMSE与非AD痴呆患者的记忆保留相关。在生存分析ACI的使用与228.75天以上的保留在参与者AD。ConclusionACI的使用率低AL和AD的居民更好的保留。版权所有© 2007约翰威利父子有限公司。
ObjectivesTo describe patterns of Acetylcholinesterase inhibitor (ACI) use in an Assisted Living (AL) population, and the association of ACIs with retention in AL.MethodsAs part of the Maryland Assisted Living Study (MD–AL), 198 residents of 22 ALs were evaluated. Dementia was diagnosed in 134, and specifically Alzheimer's disease (AD) in 79, by an expert consensus panel. Data was collected on ACI agent and dose. Vital status and location were recorded every 6 months. Other data included age, duration of residence, general medical health rating (GHMR), Mini‐Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI), Cornell Scale for Depression in Dementia (CSDD) and number of non‐psychiatric medications.ResultsThe overall ACI treatment rate was 31%. 34.5% of participants with mild to moderate AD were taking ACIs. Only two in seven participants taking rivastigmine were taking an adequate dose. Participants with AD on ACI's did not differ significantly from those not on ACI's in any of the secondary measures except age and duration of residence, those on the agents being somewhat younger and more recently admitted. For participants with AD, only ACI use was significantly associated with retention in AL at 6 months, with a relative risk of death or discharge to higher level care of 0.217. Baseline MMSE was associated with retention for those with non‐AD dementia. In a survival analysis ACI use was associated with 228.75 days longer retention in participants with AD.ConclusionACIs have low rates of use in AL and are associated with better retention for residents with AD. Copyright © 2007 John Wiley & Sons, Ltd.